Halozyme Therapeutics (NASDAQ:HALO) Sees Unusually-High Trading Volume After Strong Earnings

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw an uptick in trading volume on Friday following a stronger than expected earnings report. Approximately 1,629,126 shares were traded during mid-day trading, a decline of 9% from the previous session’s volume of 1,791,944 shares.The stock last traded at $99.7090 and had previously closed at $85.76.

The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Strong Q2 results: Halozyme reported adjusted EPS of $2.28, above the roughly $1.79-$1.82 consensus range, while revenue reached $481 million versus estimates of approximately $402 million. Revenue increased 48% year over year, and royalty revenue rose 50% to $308 million. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Raised full-year guidance: The company now expects 2026 revenue of $1.835 billion-$1.910 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS outlook is above the approximately $8.02 analyst consensus, signaling stronger expected profitability and growth.
• Positive Sentiment: Additional collaboration momentum: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s recurring royalty and licensing growth strategy. Halozyme Collaboration Agreements
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO from “market perform” to “outperform” with a $110 price target. HC Wainwright also raised its target from $95 to $115 and maintained a “buy” rating, implying substantial upside from the current trading level. Benzinga Analyst Actions
• Neutral Sentiment: The company’s earnings-call presentation and transcript provide additional details on the quarter, collaboration pipeline and operating outlook. Q2 2026 Earnings Presentation

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on HALO shares. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and set a $110.00 price objective on the stock in a research note on Friday. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday. UBS Group restated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 31st. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $89.60.

Insider Buying and Selling

In related news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares in the company, valued at $1,084,650. This represents a 33.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 1,923 shares of the firm’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total transaction of $153,397.71. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $61,245,810.60. The trade was a 0.25% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 72,477 shares of company stock valued at $5,102,643 over the last 90 days. 2.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC increased its position in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares during the period. Abel Hall LLC lifted its holdings in Halozyme Therapeutics by 4.2% in the fourth quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 129 shares during the period. StoneX Group Inc. lifted its holdings in Halozyme Therapeutics by 3.8% in the fourth quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 132 shares during the period. Moran Wealth Management LLC boosted its position in Halozyme Therapeutics by 0.4% during the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock valued at $2,396,000 after acquiring an additional 151 shares during the last quarter. Finally, Twin Capital Management Inc. boosted its position in Halozyme Therapeutics by 1.4% during the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 161 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

The stock has a fifty day simple moving average of $75.74 and a two-hundred day simple moving average of $71.25. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The stock has a market capitalization of $11.64 billion, a price-to-earnings ratio of 35.31, a P/E/G ratio of 0.35 and a beta of 0.85.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.